<DOC>
	<DOCNO>NCT01552681</DOCNO>
	<brief_summary>The purpose study find experimental study agent , baminercept , effective treating patient Sjögren 's syndrome . The study also determine study agent safely give patient Sjögren 's syndrome ; examine affect symptoms disease ; attempt understand baminercept affect underlie mechanisms Sjögren 's syndrome immune system .</brief_summary>
	<brief_title>Baminercept , Lymphotoxin-Beta Receptor Fusion Protein , Treatment Sjögren 's Syndrome</brief_title>
	<detailed_description>Sjögren 's syndrome autoimmune disorder person 's immune cell attack body 's tear salivary gland . This disease second common autoimmune disorder , affect close four million people U.S. , know cause . About one-third patient Sjögren 's syndrome enlarge parotid gland ( large salivary gland , gland make saliva ) ; inflammation organs lung joint may also occur . There known effective treatment measure relieve symptom . One bothersome symptom dryness eye mouth . Eye drop saliva stimulant ( help make saliva ) common treatment . When organ affect , symptom treat corticosteroid ( prednisone ) , non-steroidal anti-inflammatory drug ( NSAIDs , ibuprofen naproxen ) , hydroxychloroquine ( Plaquenil® ) medication suppress immune system . These drug may curb kill cell immune system , always helpful , cure Sjögren 's syndrome , many side effect .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren 's Syndrome</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Has provide write informed consent ; Between age 1875 year ( inclusive ) ; Body weight ≥ 40 kg ; Meets revise European criterion propose AmericanEuropean Consensus Group primary Sjögren 's Syndrome screening . These criterion include 3 follow 4 item : ocular symptom ; oral symptom ; Schirmer 's I test show less 6 mm wet per five minute least one eye , filamentary keratitis slit lamp examination , positive lissamine green staining ; diminish salivary production ( unstimulated whole salivary flow rate ≤ 1.5 mL/15 min ) ; PLUS , either : positive test serum SSA and/or SSB antibody , focal lymphocytic sialadenitis , focus score ≥ 1.0 per 4 millimeter ^2 ( mm^2 ) minor salivary biopsy . Stimulated salivary flow ≥ 0.1 mL/minute ( min ) ( screen ) ; Has one follow systemic manifestation Sjögren 's Syndrome lifethreatening : fatigue ( measure &gt; 50 mm 100 mm VAS ) ; joint pain ( measure &gt; 50 mm 100 mm VAS ) ; peripheral neuropathy ( document nerve conduction velocity study ) ; interstitial lung disease ( document radiography and/or alter pulmonary function test ; leukocytoclastic vasculitis ; renal tubular acidosis ; interstitial nephritis ; severe parotid swell ; extraglandular manifestation cause organ system dysfunction . If take prednisone ( equivalent corticosteroid ) , dose must ≤ 10 mg/day stable least 4 week prior Screening ; If take hydroxychloroquine , dose must stable least 12 week prior Screening ; If take cholinergic stimulant ( e.g . pilocarpine , cevimeline ) , dose must stable least 4 week prior Screening ; Subjects must agree become pregnant impregnate female . Because risk involve , participant partner ( reproductive potential ) must use two method birth control . They must continue use method 6 month stop study drug . Two birth control method list may choose : Hormonal contraception ; Male female condom without spermicide ; Diaphragm cervical cap spermicide ; Intrauterine device ( IUD ) . Has active infection exclude superficial cutaneous fungal viral infection ; Has chronic persistent infection might worsen immunosuppressive treatment ( e.g. , human immunodeficiency virus [ HIV ] , hepatitis B , hepatitis C , tuberculosis ) ; History TB positive intradermal skin test purify protein derivative ( PPD ) ; positive Mantoux test define 10 mm induration ( size raise bump , redness ) , equivalent positive TB test result , per country clinical standard , screen period . Subjects whose PPD induration ≥ 5 mm &lt; 10 mm eligible study negative chest xray screen period . There must clinical evidence TB physical examination subject . Note : Subjects prior adequate prophylaxis treatment latent TB appropriate course isoniazid equivalent , per country standard , exclude study participation . PPD administer within 6 week livevirus vaccine ; History recurrent significant infection occurrence serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) within twelve week prior Day 0 ; Receipt live vaccine within six week prior Day 0 ; History presence primary secondary immunodeficiency ; History lifethreatening allergic reaction ; Is pregnant nurse female ; Ongoing anticoagulant therapy , contraindication labial salivary biopsy tonsil biopsy ; Concurrent use anticholinergic agent , tricyclic antidepressant , antihistamine , phenothiazine , antiparkinsonian drug , antiasthmatic medication , gastrointestinal ( GI ) medication cause xerostomia 10 % patient ; Treatment follow within defined period prior Screening : 2 year rituximab ; 24 week cyclophosphamide ; 8 week azathioprine , cyclosporine , methotrexate , mycophenolate mofetil ; 4 week intravenous immunoglobulin ; 4 week etanercept ; 8 week adalimumab ; 12 week infliximab . Prednisone ( equivalent corticosteroid ) &gt; 10 mg/day ; A definite diagnosis RA , SLE , systemic sclerosis , dermatomyositis ; A history alcohol substance abuse within 12 month screen visit ; A history head neck radiation therapy , sarcoidosis , graftversushost disease ; A history malignancy , except resect basal major squamous cell carcinoma , cervical dysplasia , situ cervical cancer Grade I , within last five year ; Severe pulmonary disease manifest one follow Screening : Resting oxygen saturation &lt; 92 % ; Force vital capacity ( FVC ) &lt; 50 % predict ; Diffusion lung capacity carbon monoxide ( DLCO ) &lt; 50 % ; Abnormal laboratory result follow parameter screen visit : Absolute neutrophil count ( ANC ) : &lt; 1,500/mm^3 ; Platelets : &lt; 100,000/mm^3 ; Hemoglobin : &lt; 9 gram ( g ) /deciliter ( dL ) ; Serum creatinine : ≥ 2.0 mg/dL ; AST : &gt; 1.5x upper limit normal , ALT : &gt; 1.5x upper limit normal . A psychiatric disorder render subject incapable providing informed consent ; Plans foreign travel country Canada Western Europe within treatment period ; Inability unwillingness follow protocol ; Any condition treatment , opinion investigator , place subject unacceptable risk participant trial ; Rochester substudy subject meet follow criterion disqualify enrol tonsil biopsy substudy : Have side effect local anesthetic ( e.g. , lidocaine ) ; Have side effect silver nitrate ; Do tonsil ; Are able go 48 hour without NSAIDS ; Are able go 2 week without acetylsalicylic acid ( aspirin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>baminercept treatment</keyword>
</DOC>